Ketorolac - Neumentum
Alternative Names: Ketorolac (PMB); Ketorolac (PMC); Ketorolac pre mixed bag; Ketorolac tromethamine - Neumentum; NTM 001; NTM 002; NTM 003; Toradol - NeumentumLatest Information Update: 08 May 2026
At a glance
- Originator Neumentum
- Developer Mayo Clinic; Neumentum; Nuance Biotech
- Class 2 ring heterocyclic compounds; Azabicyclo compounds; Benzene derivatives; Carboxylic acids; Ketones; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
- Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoarthritis; Postoperative pain
Most Recent Events
- 20 Apr 2026 NEMA Research suspends a phase III trial in Postoperative pain (In adults) in the US (IV, Infusion) due to funding constraints after enrollment completion (NCT05324358)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers, In adults) in Hong Kong (IV, Infusion)
- 28 Feb 2025 Neumentum plans a phase II trial for Postoperative pain in USA (PO)(NCT06853327)